SCHEDULE: ILJIN Group Trims Aurinia Pharma Stake to 5.0%
Beneficial Ownership Amendment
ILJIN SNT and Seoung Eun Huh reduce their beneficial ownership in Aurinia Pharmaceuticals, bringing the group's total stake to 5.0%.
Summary
- ILJIN SNT Co., Ltd., ILJIN Steel Co., Ltd., ILJIN GLS Co., Ltd., Sae Kyoung Huh, Seoung Eun Huh, and Chin Kyu Huh (collectively, the "Reporting Persons") filed an amendment to their Schedule 13D.
- The Reporting Persons collectively beneficially own 6,535,141 Common Shares of Aurinia Pharmaceuticals Inc., representing 5.0% of the outstanding shares as of July 29, 2025.
- Since June 15, 2025, ILJIN SNT Co., Ltd. sold a total of 498,538 Common Shares at prices ranging from $10.22 to $11.49 per share.
- Seoung Eun Huh sold a total of 108,000 Common Shares at prices ranging from $8.56 to $8.91 per share since July 14, 2025.
- Offsetting some sales, Sae Kyoung Huh purchased 3,600 Common Shares for $22,594.70, and Seoung Eun Huh purchased 10,000 Common Shares for $55,946, both using cash on hand, since March 20, 2024.
Sentiment
Score: 3
Explanation: The filing indicates a net reduction in the beneficial ownership of Aurinia Pharmaceuticals Inc. by the ILJIN group, with significant sales by ILJIN SNT and Seoung Eun Huh outweighing minor purchases by other family members. This reduction in stake by a major investor is typically viewed as a negative signal regarding their confidence or strategic interest in the company.
Positives
- Sae Kyoung Huh and Seoung Eun Huh made minor purchases of Aurinia Pharmaceuticals Common Shares, indicating some continued individual interest.
Negatives
- The ILJIN group, primarily through ILJIN SNT and Seoung Eun Huh, engaged in significant net sales of 592,938 Common Shares of Aurinia Pharmaceuticals Inc.
Risks
- The reduction in beneficial ownership by a significant shareholder group could be perceived negatively by the market, potentially signaling a lack of confidence or a shift in investment strategy.
Future Outlook
The filing is an amendment to a Schedule 13D and does not provide forward-looking statements or guidance regarding the issuer's operations or future performance. It solely details changes in beneficial ownership by the reporting group.
Management Comments
- No notable quotes or paraphrased statements from company management of Aurinia Pharmaceuticals Inc. are included in this filing. The filing contains statements from the reporting persons regarding their ownership and disclaimer of group formation.
Industry Context
This filing reflects a change in a significant shareholder's position in Aurinia Pharmaceuticals, a company in the pharmaceutical industry. While the filing itself does not provide broader industry analysis, a reduction in stake by a major investor could be interpreted within the context of the pharmaceutical sector's current investment climate, competitive landscape, or specific developments related to Aurinia's drug pipeline or market performance. Without further context from the issuer, it is difficult to ascertain the specific industry implications of this ownership change.
Comparison to Industry Standards
- Not applicable. This filing details changes in beneficial ownership by a specific investor group and does not provide performance metrics or operational results of Aurinia Pharmaceuticals Inc. that could be compared to global benchmarks or specific comparable companies or projects.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Agreement Update | An Amended and Restated Agreement of Joint Filing, dated January 19, 2023, among the Reporting Persons was previously filed and is referenced. | January 19, 2023 | Relates to the internal governance of the reporting group's investment, not the issuer's corporate governance. |
Legal Proceedings
- None of the Reporting Persons, nor to their knowledge, any of the Covered Persons, have been convicted in a criminal proceeding or been a party to a civil proceeding subject to judgment, decree, or final order related to federal or state securities laws during the five years preceding the filing date.
Related Party Transactions
- Chin Kyu Huh is the direct owner of 100% of ILJIN GLS, indirect owner of 100% of ILJIN SNT, and owner of a majority of ILJIN Steel. He is responsible for voting and dispositive decisions of ILJIN SNT, ILJIN Steel, and ILJIN GLS.
- Sae Kyoung Huh and Seoung Eun Huh are adult daughters of Chin Kyu Huh.
- The Reporting Persons may be deemed to constitute a 'group' for Section 13(d)(3) purposes, though they disclaim admission of this.
Stakeholder Impact
- Shareholders: The reduction in stake by a significant investor group could lead to negative market sentiment and potentially impact share price.
- Management: May need to address investor concerns if the stake reduction is perceived as a lack of confidence.
Next Steps
- The filing does not explicitly state future actions, events, or milestones for Aurinia Pharmaceuticals Inc. It is an update on the beneficial ownership of a specific group.
Key Dates
| Date | Description |
|---|---|
| April 8, 2019 | Initial Schedule 13D filing. |
| June 4, 2019 | Amendment No. 1 filed. |
| November 13, 2019 | Amendment No. 2 filed. |
| December 6, 2019 | Amendment No. 3 filed. |
| December 9, 2019 | Amendment No. 4 filed. |
| December 10, 2019 | Amendment No. 5 filed. |
| December 18, 2019 | Amendment No. 6 filed. |
| July 23, 2020 | Amendment No. 7 filed. |
| October 9, 2020 | Amendment No. 8 filed. |
| January 26, 2021 | Amendment No. 9 filed. |
| January 27, 2021 | Amendment No. 10 filed. |
| March 3, 2022 | Amendment No. 11 filed. |
| January 6, 2023 | Amendment No. 12 filed. |
| January 19, 2023 | Amended and Restated Agreement of Joint Filing dated. |
| January 20, 2023 | Amendment No. 13 filed. |
| May 10, 2023 | Amendment No. 14 filed. |
| March 20, 2024 | Amendment No. 15 filed. |
| June 15, 2025 | Date from which sales transactions are reported. |
| July 14, 2025 | Seoung Eun Huh sold 48,000 shares. |
| July 15, 2025 | Seoung Eun Huh sold 20,000 shares. |
| July 16, 2025 | Seoung Eun Huh sold 30,000 shares. |
| July 23, 2025 | Seoung Eun Huh sold 10,000 shares. |
| July 29, 2025 | Date of 131,629,546 Common Shares outstanding reported by Issuer. |
| July 30, 2025 | Issuer's Quarterly Report on Form 10-Q filed. |
| August 1, 2025 | ILJIN SNT sold 200,000 shares. |
| August 4, 2025 | ILJIN SNT sold 150,000 shares. |
| August 11, 2025 | Date of event requiring filing; ILJIN SNT sold 36,354 shares. |
| August 12, 2025 | ILJIN SNT sold 112,184 shares. |
| August 13, 2025 | Date of filing signature. |
Recommendation
sellThe filing indicates significant net selling activity by a major investor group, the ILJIN group, which reduced its beneficial ownership in Aurinia Pharmaceuticals. This divestment, totaling 592,938 net shares sold, suggests a potential decrease in conviction or a strategic reallocation of capital by a major holder. This could be interpreted as a negative signal regarding the company's future prospects from an informed investor, warranting a 'sell' recommendation for investors to re-evaluate their position.
Keywords
Aurinia Pharmaceuticals, ILJIN SNT, ILJIN Steel, ILJIN GLS, Schedule 13D, beneficial ownership, stock sales, pharmaceutical, common shares, institutional investor, stake reduction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.